Becton Dickinson pledges $19B for tariff relief

Becton Dickinson on Tuesday said it will invest $19 billion in the U.S. over several years for relief from future tariffs. $3 billion is earmarked to expand domestic manufacturing, more than $1 billion of it for Nebraska. BD plans to add about 5 billion essential medical consumables a year from U.S. plants, raising the domestically supplied share to roughly 80%. All needles used in the U.S. will be made domestically with American-made steel. Trump outlined part of the deal Monday on social media and said medical device tariffs would be in place by year-end, writing: "BUILD IN AMERICA, HIRE AMERICAN WORKERS, AND TREAT AMERICAN PATIENTS FAIRLY - OR PAY!" BD is the first major U.S. medical device company to strike such a government deal. U.S. sites include Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina. Relief is tied to Section 232 and hinges on final measure scope and BD hitting agreed milestones. The company has not quantified the financial impact. No factual disputes appear in the record.